We've known that Intercept Pharmaceuticals Inc.'s FLINT trial evaluating obeticholic acid (OCA) for the treatment of nonalcoholic steatohepatitis (NASH) was positive since the data safety monitoring stopped the trial early for positive efficacy in January. (See BioWorld Today, Jan. 10, 2014.)